Exagen Inc. Announces Study to Evaluate Emergence of Autoimmune Diseases After COVID-19 Infection
November 02 2020 - 8:25AM
Exagen Inc. (Nasdaq: XGN), an organization dedicated to
transforming the care continuum for patients suffering from
autoimmune diseases, announced today a new study in collaboration
with Brigham and Women’s Hospital in Boston, MA. The Brigham is
acknowledged internationally for its expertise and innovation in
patient care, biomedical research, and educational training
programs for physicians, scientists, and health care professionals.
As viruses are implicated in the development of autoimmune
diseases, there is the need to understand the effects of the
current COVID-19 pandemic on the development of rheumatic
autoimmune diseases. This study will evaluate the incidence and
risk factors for onset of rheumatic autoimmune diseases in people
who recovered from COVID-19.
Positive polymerase chain reaction (PCR)-confirmed COVID-19
patients from the Brigham will be invited to partake in the
year-long evaluation. Patients will be categorized by COVID-19
severity: mild (outpatient), moderate (inpatient, not ICU), and
severe (ICU). Patients who elect to participate will be assessed
with two validated questionnaires and tested using AVISE®
biomarkers to investigate the new onset of rheumatic disease
symptoms and autoantibodies in the 3 months to 1 year following
onset of COVID-19.
“True incidence rates and risk factors associated with
autoimmune and rheumatic diseases arising after COVID-19 are not
known. We are proud to work with Brigham and Women’s Hospital,
particularly their strong rheumatic disease epidemiology research
team, to examine this further,” said Ron Rocca, President and CEO
of Exagen.
About Exagen Inc.
Exagen is dedicated to transforming the care continuum for
patients suffering from debilitating and chronic autoimmune
diseases by enabling timely differential diagnosis and optimizing
therapeutic intervention. Exagen has developed and is
commercializing a portfolio of innovative testing products under
its AVISE® brand. Several of these products are based on our
proprietary Cell-Bound Complement Activation Products, or CB-CAPs,
technology. CB-CAPs assess the activation of the complement system,
a biological pathway implicated in systemic lupus erythematosus, or
SLE. Exagen’s goal is to enable rheumatologists to improve care for
patients through the differential diagnosis, prognosis and
monitoring of complex autoimmune and autoimmune-related diseases,
including SLE and rheumatoid arthritis, or RA. Exagen’s model of
integrating testing products and therapeutics
positions Exagen to offer targeted solutions to
rheumatologists and, ultimately, better serve patients. For more
information, please visit www.Exagen.com.
Forward Looking Statements
Exagen cautions you that statements contained in this press
release regarding matters that are not historical facts are
forward-looking statements. These statements are based on the
company’s current beliefs and expectations. Such forward-looking
statements include, but are not limited to, statements regarding
the study in collaboration with the Brigham and any potential
findings related to the incidence and risk factors for consent of
rheumatic autoimmune diseases in people who recovered from
COVID-19. The inclusion of forward-looking statements should not be
regarded as a representation by Exagen that any of its
plans will be achieved. Actual results may differ from those set
forth in this press release due to the risks and uncertainties
inherent in Exagen’s business, including, without limitation: the
COVID-19 pandemic may continue to adversely affect our business,
financial condition and results of operations, including as a
result of shutdowns of our facilities and operations as well as
those of our suppliers and courier services, impeding patient
movement and interruptions to healthcare services causing a
decrease in test volumes, disruptions to the supply chain of
material needed for our tests, our sales and commercialization
activities and our ability to receive specimens and perform or
deliver the results from our tests, delays in reimbursement and
coverage decisions from Medicare and third-party payors and in
interactions with regulatory authorities, and delays in ongoing and
planned clinical trials involving our tests; the company’s
commercial success depends upon attaining and maintaining
significant market acceptance of its testing products and promoted
therapeutics among rheumatologists, patients, third-party payers
and others in the medical community; the company’s ability to
successfully execute on its Dx/Rx strategy, including its promotion
efforts for SIMPONI®; third party payers not providing coverage and
adequate reimbursement for the company’s testing products or
promoted therapeutics; the company’s ability to obtain and maintain
intellectual property protection for its testing products;
regulatory developments affecting the company’s business; and other
risks described in the company’s prior press releases and the
Company’s filings with the Securities and Exchange
Commission (SEC), including under the heading “Risk Factors”
in the company’s Annual Report on Form 10-K and any subsequent
filings with the SEC. You are cautioned not to place undue
reliance on these forward-looking statements, which speak only as
of the date hereof, and Exagen undertakes no obligation
to update such statements to reflect events that occur or
circumstances that exist after the date hereof. All forward-looking
statements are qualified in their entirety by this cautionary
statement, which is made under the safe harbor provisions of the
Private Securities Litigation Reform Act of 1995.
InvestorsWestwicke PartnersMike
CavanaughMike.Cavanaugh@westwicke.com 646.677.1838
CompanyExagen Inc.Kamal Adawi, Chief Financial
Officerkadawi@exagen.com760.477.5514
Exagen (NASDAQ:XGN)
Historical Stock Chart
From Jul 2024 to Aug 2024
Exagen (NASDAQ:XGN)
Historical Stock Chart
From Aug 2023 to Aug 2024